Ionis Parmaceuticals Treating Hereditary Angioedema
On May 31, 2024, Ionis Pharmaceuticals (IONS) announced positive results from two Phase 3 OASIS-HAE and OASIS plus studies of the firm’s Donidalorsen in patients with hereditary angioedema (HAE).

• Donidalorsen demonstrating a sustained significant reduction in monthly HAE attack rates and continued attack rate improvement of >90% after one year treatment . . .
  
  This content is for paid subscribers.
  Please click here to subscribe or here to log in.
  Impacting News

  Ionis Pharmaceuticals Inc (IONS)

  June 3, 2024
  Tweet Pin It